NCT07053020View on ClinicalTrials.gov

A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2030

Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG

Cytarabine

Given by intravenous adminstration

DRUG

Oral Cladribine

Given Orally

Trial Locations (1)

77030

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT07053020 - A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter